Lincoln Pharmaceuticals Share Price in Focus After Q1 FY26; FIIs Increases Stake to 5.13%

Lincoln Pharmaceuticals Limited announced  Q1FY26 financial performance on August 7, 2025, reporting standalone net profit of ₹27.70 crore compared to ₹23.69 crore in Q1 FY25. The Gujarat-based healthcare company demonstrated robust growth across key financial metrics whilst advancing its global expansion strategy.

Total Income Grows 7.39% to ₹169.34 Crore with Strong EBITDA Performance

Total income for Q1 FY26 increased 7.39% year-on-year to ₹169.34 crore from ₹157.69 crore in Q1 FY25. EBITDA surged 17.92% to ₹39.08 crore from ₹33.14 crore, demonstrating improved operational efficiency. Earnings per share stood at ₹13.82, reflecting the company's strong profitability momentum across its pharmaceutical operations.

FII Stake Increases to 5.13%

Foreign Institutional Investors steadily raised their holding from 3.95% in June 2024 to 5.13% by June 2025, indicating growing investor confidence. The company targets a 15-18% annual growth rate driven by strong performance in cardiac, diabetic, dermatology, and ENT segments whilst expanding its high-value product lines and market presence.

Read More: Aurobindo Pharma Q1FY26 Results: Revenue and PAT Declined Over 6%!

₹1,000 Crore Revenue Target Within 3 Years Through Global Expansion

Lincoln Pharmaceuticals aims to achieve ₹1,000 crore revenue within 3 years through business expansion and new market entry. Currently exporting to 60+ countries across multiple continents, the company plans to expand its footprint to 90 countries over the next 2-3 years with recent Canadian market entry and EU GMP approvals.

Bulk Drug Manufacturing Plant Operational with ₹4 Crore Investment

The company commenced bulk drug manufacturing plant operations in Q1 FY26, receiving product approvals for 10 products with others under process. Management plans ₹4 crore investment for this facility from internal accruals, supporting the company's vertical integration strategy whilst maintaining a strong balance sheet with no term debt.

Lincoln Pharmaceuticals Share Price Performance

On August 8, 2025, Lincoln Pharmaceuticals share price opened at ₹594 on NSE, below the previous close of ₹601.10. During the day, it surged to ₹594.00 and dipped to ₹569.90. The stock is trading at ₹573.00 as of 10:01 AM. The stock registered a significant decline of 4.67%.

Over the past week, it has moved up by 7.79%, over the past month, it has moved up by 4.21%, and over the past 3 months, it has moved up by 1.53%.

Conclusion

Lincoln Pharmaceuticals' Q1 FY26 performance with ₹27.70 crore net profit growth of 16.93% and total income rise to ₹169.34 crore demonstrates strong operational execution. With FII stake increasing to 5.13%, a ₹1,000 crore revenue target in 3 years, and expansion to 90 countries planned. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities are subject to market risks. Read all related documents carefully before investing.